Boehringer Ingelheim pipeline at a glance (June 2026)
About the Boehringer Ingelheim clinical program
Boehringer Ingelheim is a privately-held pharmaceutical company with major franchises in respiratory disease, metabolic conditions, and oncology. In respiratory, Ofev (nintedanib) for idiopathic pulmonary fibrosis and other fibrosing ILDs continues expanding into new fibrosing lung conditions, while Spiriva and Spiolto anchor the COPD franchise. In metabolic disease, Jardiance (empagliflozin) — co-developed with Eli Lilly — has expanded from type 2 diabetes into heart failure with reduced and preserved ejection fraction, and is advancing into CKD. Their oncology pipeline focuses on novel mechanisms in solid tumors, including KRAS SOS1 inhibitors, KRASG12C inhibitors, and immune cell engagers targeting tumor microenvironment.
Key therapeutic areas
- Respiratory (IPF, ILD, COPD)
- Metabolic / cardiovascular (SGLT2, HFpEF)
- Oncology (KRAS, SOS1, tumor microenvironment)
- Immunology / inflammation
- CNS
Key pipeline programs
- Jardiance (empagliflozin) — SGLT2, T2D/HF/CKD
- Ofev (nintedanib) — FGFR, PDGFR, VEGFR
- Gilotrif (afatinib) — EGFR/HER2 inhibitor, NSCLC
- BI 1701963 — SOS1 inhibitor, KRAS-mutant tumors
- BI 905677 — KRASG12C inhibitor
- Spesolimab — IL-36R, generalized pustular psoriasis
Monitor the Boehringer Ingelheim pipeline daily
Get alerts when Boehringer Ingelheim registers new trials or updates existing protocols. Free plan — no credit card required.
Start Monitoring FreeTop Boehringer Ingelheim trial indications
| Condition / Indication | Trials |
|---|---|
| ["Healthy"] | 46 |
| ["Lung Diseases, Interstitial"] | 6 |
| ["Solid Tumors"] | 5 |
| ["Obesity"] | 5 |
| ["Idiopathic Pulmonary Fibrosis"] | 4 |
| ["Kidney Disease, Chronic"] | 4 |
| ["Neoplasms"] | 4 |
| ["Heart Failure"] | 3 |
Why monitor Boehringer Ingelheim's clinical trial activity
Boehringer Ingelheim's SOS1 inhibitor (BI 1701963) in combination with KRAS G12C inhibitors is a major competitive program for anyone active in KRAS-altered NSCLC or CRC. Their Jardiance expansions into HFpEF and CKD are closely watched by companies developing competing SGLT2 or HF therapeutics.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Boehringer Ingelheim's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks Boehringer Ingelheim trials
- Sponsor normalization: Boehringer Ingelheim may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Boehringer Ingelheim pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get Started FreeFrequently asked questions
What is Boehringer Ingelheim's focus in oncology trials?
BI's oncology pipeline focuses on novel mechanisms — particularly KRAS pathway inhibition (SOS1 inhibitor BI 1701963 in combination with sotorasib or adagrasib) and tumor microenvironment programs. They are less focused on traditional chemotherapy or checkpoint inhibitor combinations and more on synthetic lethality and signaling pathway combinations.
How many Boehringer Ingelheim trials are currently recruiting?
Based on current ClinicalTrials.gov data, 46 Boehringer Ingelheim-sponsored trials are actively recruiting patients across respiratory, metabolic, and oncology programs.
Is Boehringer Ingelheim's pipeline data available on DataLookout despite being a private company?
Yes. ClinicalTrials.gov registration is required by law for trials conducted under IND in the US regardless of company type. Boehringer Ingelheim registers all Phase 1+ trials on ClinicalTrials.gov, making their pipeline visible and trackable through DataLookout.